Clinical observation of postoperative hepatic arterial infusion and systemic adjuvant chemotherapy in patients with stage Ⅲcolorectal cancer

Yu XIAO,Hongyan LI,Liwen MA,Zhaohui ZHANG,Li LIANG,Mopei WANG,Baoshan CAO
DOI: https://doi.org/10.3969/j.issn.1000-8179.2013.01.009
2013-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective: This study aims to investigate whether postoperative hepatic arterial infusion combined with systemic adjuvant chemotherapy is more effective compared with systemic adjuvant chemotherapy alone in terms of survival and liver metastasis for patients with stage Ⅲ colorectal cancer.Methods: From January 2002 to March 2006,21 patients with stage Ⅲ colorectal cancer were assigned to postoperative locoregional chemotherapy with fluorodeoxyuridine and systemic adjuvant chemotherapy with oxaliplatin(treatment group).Another group of 21 patients were assigned to the systemic adjuvant chemotherapy with oxaliplatin as well as fluorouracil and folinic acid(control goup).The primary endpoint of the observation included 5-year disease-free survival(DFS) and liver metastasis.The secondary endpoint was the overall survival(OS) and toxic effects.Results: Median follow-up was 65 months(range: 9 months to 119 months).The incidence rate of liver metastasis in patients who underwent hepatic arterial infusion and systemic chemotherapy was 9.5%,whereas that in patients who underwent systemic chemotherapy alone was calculated at 28.6%(P=0.109).By contrast,the incidence of lung metastasis was relatively higher;however,the difference was not significant(28.6% vs.14.3%,P =0.256).No significant difference in the 5-year DFS(38.1% vs.42.9%,P=0.671) and the 5-year OS(47.9%vs.45.0%,P=0.784) was indicated between the two groups.Toxicities such as reduction in leukocytes as well as nausea and peripheral neurosensory toxicity were mild and could be treated by medication.Conclusion: Postoperative hepatic arterial infusion combined with systemic chemotherapy can possibly reduce the occurrence of liver metastasis,but may add no further benefit to the DFS and OS of the patients with stage Ⅲ cancer obtaining systemic chemotherapy alone.The toxicities were mild and tolerable.
What problem does this paper attempt to address?